Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

If you have an opening in your portfolio for a great stock with solid growth potential and perhaps even a respectable dividend yield, you would do well to give Pfizer (NYSE: PFE) some serious ...

Pfizer appears to be a very promising stock to buy if you're looking for income. That 7.3% dividend yield is terrific, and even if it gets slashed, it will likely still be substantial.

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations. Arvinas on ...

BEIJING (Reuters) -Global manufacturers have raised the alarm on China’s decision to curb exports of rare earths alloys, mixtures and magnets. Here is an overview of rare earths and China’s ...

Alarm over China’s stranglehold on critical minerals grew on Tuesday as global automakers joined their U.S. counterparts to complain that restrictions by China on exports of rare earth alloys ...

Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a ...

Jim Cramer recently gave a thumbs-up to Pfizer, pointing to its strong drug pipeline and major acquisition moves. A caller highlighted Pfizer’s promising phase three candidates and its licensing deal ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discussed recently. A caller highlighted Pfizer Inc.’s (NYSE:PFE ...